magazine.pharmamkt.net
AstraZeneca’s Imfinzi fails to meet main goals in head and neck cancer study
AstraZeneca Plc’s immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday.